Virtual Library

Start Your Search

Ashok Muniappan

Author of

  • +

    P1.12 - Small Cell Lung Cancer/NET (Not CME Accredited Session) (ID 944)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.12-17 - Overall Survival and Recurrence After Surgical Resection of Pure and Mixed Large Cell Neuroendocrine Tumors. (ID 13051)

      16:45 - 18:00  |  Author(s): Ashok Muniappan

      • Abstract
      • Slides


      Large-cell neuroendocrine carcinoma (LCNC) is an aggressive tumor with poor prognosis and undefined treatment. We performed a retrospective analysis on the outcomes of surgical resection and adjuvant therapy to assess the effectiveness of treatment.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      Retrospective review of patients with LCNC who underwent surgical resection at a single-center tertiary care facility from 2002-2017. Survival times were assessed from day of surgery until death. A Kaplan-Meier method for overall survival (OS) and for recurrence was used and compared across prognostic factors using log-rank analysis and a Cox proportional hazard model.

      4c3880bb027f159e801041b1021e88e8 Result

      Sixty-two patients were identified with a median follow up of 3.4 years. Of these, 26 (41.9%) were male and 56 (90.3%) were current or former smokers. The majority of patients underwent a lobectomy/segmentectomy (72.6%), while a smaller percentage (14.5%) underwent wedge resection, and the remainder pneumonectomy or bi-lobectomy (4.8%). Pathologically, 31 (54.4%) were stage I, 20 (35.1%) stage II, and 6 (10.5%) stage III-IV. Additionally, 35 (56.4%) represented pure LCNC while the remaining 27 (43.6%) had a mixed histology. Median OS for resected stage I disease was 11.3 years, decreased to 4.4 years in stage II disease, and was 0.8 years in stage III-IV disease (p = 0.01) (Figure 1). For those that recurred, median time to recurrence was 1.20 years for stage I and 1.15 years for stage II disease. Adjuvant therapy, type of resection, and tumor histology (pure vs. mixed) had no significant impact on OS on unadjusted or adjusted analysis.


      8eea62084ca7e541d918e823422bd82e Conclusion

      LCNC is associated with early recurrence after surgical resection and poor survival for patients with stage III and IV disease. In patients with mixed histology survival and recurrence remain similar to those with pure LCNC tumors.


      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.